– USA, MA – Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the election of Jennifer Good to its Board of Directors. In addition, Rhythm thanked Neil Exter, a partner at Third Rock Ventures and member of the Company’s Board of Directors since April 2014, who did not seek re-election.
“We are pleased to welcome Jennifer to our Board of Directors,” said Keith Gottesdiener, M.D., CEO of Rhythm. “Jennifer has experience leading and growing publicly-held life sciences companies as chief executive officer, and she is a valued board member for biotechnology companies and patient advocacy organizations. We are confident she will bring extensive experience and deep industry insights to guide Rhythm to our next stage of growth as we seek to further cement our Company as the partner of choice to patients, physicians, and families living with rare genetic disorders of obesity. Also, on behalf of Rhythm, I thank Neil for his service and leadership in helping Rhythm mature into a late-stage company with Phase 3 trials in four indications.”
About Jennifer Good
Ms. Good is Co-founder, President and Chief Executive Officer, and a member of the Board of Directors of Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Prior to co-founding Trevi in 2011, she served in various roles at Penwest Pharmaceuticals Co., including President and Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, while leading the transition of the publicly-traded company from development stage to generating annual revenues of more than $50 million, until the Company was acquired by a strategic partner in 2010. Ms. Good served on the board of Juniper Pharmaceuticals, Inc. until its acquisition by Catalent, Inc. in 2018. She also currently serves as a board member of the Friedreich’s Ataxia Research Alliance, a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, since 2011.
“I’m excited to join Rhythm at such a transformational time, as the Company works toward its first two pivotal topline data readouts for setmelanotide and advances its ongoing development efforts into additional MC4R pathway-driven disorders of obesity,” said Ms. Good. “I look forward to working with management and the Board to advance Rhythm’s goals of building an integrated community to better support patients, families and care providers and of delivering setmelanotide as the first approved therapy for rare genetic disorders of obesity.”
Ms. Good holds a B.B.A. from Pacific Lutheran University.
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the company’s first-in-class MC4R agonist, in Phase 3 studies in patients with POMC deficiency obesity, LEPR deficiency obesity, BBS, and Alström syndrome. Rhythm is dedicated to improving the understanding of severe obesity that results from specific genetic disorders.
For more information: https://www.rhythmtx.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.